Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study
Raymond L Benza, Athénaïs Boucly, Harrison W Farber, Adaani E Frost, Hossein-Ardeschir Ghofrani, Marius M Hoeper, Marc Lambelet, Claudia Rahner, Sameer Bansilal, Sylvia Nikkho, Christian Meier, Olivier Sitbon, Raymond L Benza, Athénaïs Boucly, Harrison W Farber, Adaani E Frost, Hossein-Ardeschir Ghofrani, Marius M Hoeper, Marc Lambelet, Claudia Rahner, Sameer Bansilal, Sylvia Nikkho, Christian Meier, Olivier Sitbon
Abstract
Background: Risk assessment is essential in pulmonary arterial hypertension (PAH) management. We investigated the effect of riociguat on REVEAL Lite 2 score, an abridged version of the REVEAL risk score, and its association with long-term outcomes in PATENT.
Methods: PATENT-1 was a randomized, double-blind study of riociguat vs placebo in patients with PAH. In the PATENT-2 open-label extension, all patients received riociguat up to 2.5 mg three times daily (n = 396). REVEAL Lite 2 scores were calculated at baseline, PATENT-1 Week 12, and PATENT-2 Week 12, with patients stratified as low- (1-5), intermediate- (6-7), or high-risk (≥8). Kaplan-Meier and Cox proportional hazards analyses assessed association of riociguat with survival and clinical worsening-free survival (CWFS).
Results: REVEAL Lite 2 score improved with riociguat 2.5 mg at PATENT-1 Week 12 (least-squares mean difference vs placebo: -0.8; p = 0.0004). More patients receiving riociguat 2.5 mg stabilized or improved risk stratum at PATENT-1 Week 12 vs placebo (p = 0.0005) and achieved low-risk status. REVEAL Lite 2 score at baseline and PATENT-1 Week 12 were associated with survival and CWFS (all p < 0.0001), as was change in score from baseline to Week 12 (p = 0.0002 and p < 0.0001, respectively). Survival and CWFS differed between risk strata at baseline (p < 0.0001) and PATENT-1 Week 12 (p < 0.0001).
Conclusions: This analysis confirms the risk-reduction benefits of riociguat in patients with PAH and further contributes to the validation of REVEAL Lite 2 in facilitating PAH risk assessment.
Keywords: pulmonary arterial hypertension; riociguat; risk assessment.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed